Accustem Sciences Inc.

Accustem Sciences Inc.

ACUT - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.9M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Accustem Sciences Inc.Accustem Sciences Inc.-1.1-52%--
$-0.00

Current Fair Value

100.5% downside

Overvalued by 100.5% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$1.90 Million
Enterprise Value$1.88 Million
Earnings per Share$-0.12
Beta1.89
Outstanding Shares16,072,267

Return

Return on Equity52.23%ROE
Return on Assets-3753.74%
Return on Invested Capital53.87%

Valuation & Multiples

P/E Ratio-1.11P/E Ratio
PEG-0.3PEG
Price to Sales-Price to Sales
Price to Book Ratio-0.12Price to Book Ratio
Enterprise Value to Revenue19.12
Enterprise Value to EBIT-0.58
Enterprise Value to Net Income-1
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 14, 2026
EPS
-$0.02
Reported
Revenue
$98,400
Reported

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Accustem Sciences Inc.

4 employees
CEO: Wendy E. Blosser

AccuStem Sciences, Inc. operates as a life science firm committed to improving the outlook for individuals battling cancer. Its primary innovation is the StemPrintER technology, an advanced multi-gene prognostic assay designed to predict...